These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2794972)

  • 1. Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge.
    Weir JP; Bennett M; Allen EM; Elkins KL; Martin S; Rouse BT
    J Gen Virol; 1989 Oct; 70 ( Pt 10)():2587-94. PubMed ID: 2794972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An adenovirus-herpes simplex virus glycoprotein B recombinant (Ad-HSV.gB) protects mice against a vaccinia HSV.gB and HSV challenge.
    Endresz V; Berencsi K; Gönczöl E
    Acta Microbiol Immunol Hung; 1995; 42(3):247-54. PubMed ID: 8548197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity.
    Allen EM; Weir JP; Martin S; Mercadal C; Rouse BT
    Viral Immunol; 1990; 3(3):207-15. PubMed ID: 2175194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proportion of herpes simplex virus-specific cytotoxic T lymphocytes (Tc) that recognize glycoprotein C varies between individual mice and is dependent on the form of immunization.
    Martin S; Mercadal CM; Weir JP; Rouse BT
    Viral Immunol; 1993; 6(1):21-33. PubMed ID: 8386515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.
    Cantin EM; Eberle R; Baldick JL; Moss B; Willey DE; Notkins AL; Openshaw H
    Proc Natl Acad Sci U S A; 1987 Aug; 84(16):5908-12. PubMed ID: 3303033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus.
    Forrester AJ; Sullivan V; Simmons A; Blacklaws BA; Smith GL; Nash AA; Minson AC
    J Gen Virol; 1991 Feb; 72 ( Pt 2)():369-75. PubMed ID: 1704412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins.
    Nass PH; Elkins KL; Weir JP
    J Infect Dis; 1998 Sep; 178(3):611-7. PubMed ID: 9728527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins.
    Martin S; Cantin E; Rouse BT
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1359-70. PubMed ID: 2543783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.
    Paoletti E; Lipinskas BR; Samsonoff C; Mercer S; Panicali D
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):193-7. PubMed ID: 6320164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live vaccinia virus recombinants expressing herpes simplex virus genes.
    Rooney JF; Wohlenberg CR; Moss B; Notkins AL
    Rev Infect Dis; 1991; 13 Suppl 11():S898-903. PubMed ID: 1664124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and characterization of herpes simplex virus type 1 (HSV-1) glycoprotein G (gG) by recombinant vaccinia virus: neutralization of HSV-1 infectivity with anti-gG antibody.
    Sullivan V; Smith GL
    J Gen Virol; 1987 Oct; 68 ( Pt 10)():2587-98. PubMed ID: 2822841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
    Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
    J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection.
    Martin S; Rouse BT
    J Immunol; 1987 May; 138(10):3431-7. PubMed ID: 3033075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
    Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
    J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
    Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B
    Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Construction and the immunogenicity of the recombinant Modified Vaccinia Virus Ankala co-expressing ORF4, ORF5 and ORF6 genes of porcine reproductive and Respiratory Syndrome Virus NJ-a strain].
    Zheng QS; Bi ZX; Li P; Chen DS; Chen PY
    Wei Sheng Wu Xue Bao; 2007 Apr; 47(2):345-9. PubMed ID: 17552247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge.
    Banks TA; Jenkins FJ; Kanangat S; Nair S; Dasgupta S; Foster CM; Rouse BT
    Virology; 1994 Apr; 200(1):236-45. PubMed ID: 8128625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion of the carboxy-terminus of herpes simplex virus type 1 (HSV-1) glycoprotein B does not affect oligomerization, heparin-binding activity, or its ability to protect against HSV challenge.
    Lin XH; Ali MA; Openshaw H; Cantin EM
    Arch Virol; 1996; 141(6):1153-65. PubMed ID: 8712932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.